BUSINESSJun 7 · 11:00 UTCSCMP WORLDJulie Zhang

Which company could become the Chinese Pfizer? Here are analysts’ top picks

Chinese biotechnology companies may begin selling their own drugs in Europe and the US within 10 to 15 years, according to policy and industry analysts. Discussions among investors and analysts focus on which companies will achieve international brand recognition through outlicensing agreements.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Chinese biotechnology companiestopicEuropeplaceUnited Statesplaceoutlicensing agreementstopicPfizerorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 7 · 11:00 UTC
Which company could become the Chinese Pfizer? Here are analysts’ top picks
BUSINESSJun 3 · 11:06 UTC
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
BUSINESSMay 26 · 08:20 UTC
Hong Kong-Listed Biotech Insilico Is Said to Explore UAE Listing
TECHNOLOGYMay 21 · 06:00 UTC
Alibaba signals next phase of AI growth from investment to commercialisation
BUSINESSApr 27 · 16:04 UTC
Italy’s Angelini Said to Explore Catalyst Pharma Acquisition
BUSINESSMay 21 · 06:00 UTC
Alibaba signals next phase of AI growth from investment to commercialisation